A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(8 sites)

Canada

University of Calgary, Calgary, Alberta

Ottawa Hospital Research Institute (OHRI), Ottawa, Ontario

CIUSSS du Saguenay-Lac-Saint-Jean, Chicoutimi, Quebec

Montreal Neurological Institute, Montreal, Quebec

New Zealand

Pacific Clinical Research Network Auckland, Takapuna, Auckland

United Kingdom

Salford Royal Hospital, Salford, England

University College London Hospitals NHS Foundation Trust, London, UK

Newcastle Upon Tyne Hospitals, Newcastle upon Tyne